Clinical trials: Mental Disorder
Attention Deficit Hyperactivity Disorder
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B).
- Trial name
- NCT04085172
- Testing
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 396 people
- Sponsor
- Shire
Alzheimer's Disease
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of BMS-708163 administered as single and multiple doses in Chinese subjects
- Trial name
- NCT01079819
- Testing
- BMS-708163
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Bristol-Myers Squibb
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
- Trial name
- NCT06068465
- Testing
- pimavanserin tartrate
- Where
- 60 sites in China
- Volunteers
- 248 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects.
- Trial name
- NCT01423916
- Testing
- OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg)
- Where
- 8 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease, Cognition Disorder
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856
The multiple ascending dose (MAD) design of the study is based on the aim to study safety, tolerability, PK and pharmacodynamics of selected doses of ACD856 in a limited number of healthy volunteers.
- Trial name
- NCT05077501
- Testing
- ACD856
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AlzeCure Pharma
Acute Schizophrenia
A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia
This is a randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), active-controlled…
- Trial name
- NCT00350467
- Testing
- ER OROS paliperidone and Olanzapine
- Where
- 7 sites in China
- Volunteers
- 288 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Parkinson's Disease Psychosis
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00658567
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 123 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Attention Deficit Hyperactivity Disorder
Cognitive ADHD Videogame Exploratory Study
A study in ADHD and neuro-typical children to assess EVO game play over 29 days.
- Trial name
- CAVES (NCT01943539)
- Testing
- Neuro-typical controls and ADHD will receive EVO game play.
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Akili Interactive Labs, Inc.
Cognitive Disorders
EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
The purpose of this study is to determine the effectiveness of EGb 761® (Tanakan®) in Russian patients of middle age and younger, suffering from psycho-emotional symptoms added to cognitive disorders based on the improvement of…
- Trial name
- TAYPES (NCT02321475)
- Testing
- EGb761®
- Where
- 2 sites in Russia
- Volunteers
- 54 people
- Sponsor
- Ipsen
Mild Cognitive Impairment
Five Lives MED to Improve Cognitive Function in Mild Cognitive Impairment
The goal of this randomized controlled trial is to determine whether the digital health app Five Lives MED can improve cognitive function in people with mild cognitive impairment (MCI).
- Trial name
- NCT06598163
- Testing
- Five Lives MED
- Where
- 7 sites in France, United Kingdom
- Volunteers
- 170 people
- Sponsor
- SharpTx
Depressive Symptoms, Anxiety Disorders and Symptoms
Evaluating a Virtual Mentoring Program Plus Mental Health Videos for Teens
This clinical trial evaluates Appa Health, a mental health smartphone and computer app for teenagers. Appa is built from two components.
- Trial name
- NCT06138730
- Testing
- Appa Complete, Appa Lite
- Where
- United States
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Appa Health
Vascular Dementia
The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD).
- Trial name
- NCT01978730
- Testing
- high dose group of SaiLuoTong capsule, low dose group of SaiLuoTong, the control group
- Where
- 16 sites in China
- Volunteers
- 372 people
- Sponsor
- Shineway Pharmaceutical Co.,Ltd
Generalized Anxiety Disorder, Panic Disorder
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and…
- Trial name
- NCT00266409
- Testing
- Niravam, SSRI/SNRI
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- UCB Pharma
Insomnia Disorder
Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder
The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
- Trial name
- NCT06975514
- Testing
- YZJ-1139, Zolpidem
- Where
- 16 sites in China
- Volunteers
- 61 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Obsessive Compulsive Disorder
A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item…
- Trial name
- NCT01933919
- Testing
- Fluvoxamine maleate
- Volunteers
- 38 people
- Sponsor
- AbbVie
Major Depressive Disorder, Personality Disorder
Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial
Background: According to the WHO, major depressive disorder is the second largest healthcare problem worldwide in terms of disability caused by illness.
- Trial name
- Mipsy (NCT01070134)
- Testing
- Mindfulness-based Behavioural Therapy (MIBT), PT (psychodynamic therapy)
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Psychiatry Roskilde
Bipolar Disorders
Open-label Adjunctive Zonisamide for Bipolar Disorder
To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
- Trial name
- NCT00047567
- Testing
- zonisamide
- Volunteers
- 20 people
- Sponsor
- Elan Pharmaceuticals
Mood and Sleep Quality
A Study to Evaluate the Efficacy of VL-NL-02 on Sleep Quality.
The goal of this clinical trial is to study the impact of VL-NL-02 in improving sleep quality, restorative sleep complaints, quality of life, stress levels, and sleep stages.
- Trial name
- NCT06056258
- Testing
- VL-NL-02
- Where
- 5 sites in India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Insomnia, Sleep Initiation and Maintenance Disorders
Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
This study was conducted to investigate the efficacy of treatment with Org 50081 (Esmirtazapine) compared to placebo in elderly participants with chronic primary insomnia.
- Conditions
- Insomnia, Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias
- Trial name
- NCT00561821
- Testing
- Esmirtazapine
- Volunteers
- 538 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.